SlideShare a Scribd company logo
Overview of HIV/AIDS
In Ethiopia
Unit 1
HIV Care and ART: A Course for
Pharmacists by Salahadin M.Ali
Overview of HIV/AIDS 2
Learning Objectives
■ Describe global & national HIV/AIDS
epidemiological profile
■ Describe the Ethiopian National AIDS Policy
■ Describe the Ethiopian National Strategy for
Prevention and Control of HIV/AIDS
■ Understand Implementation status of HIV/AIDS
program in Ethiopia
Global and National Summary of
HIV/AIDS Epidemic
Overview of HIV/AIDS 4
Global Summary of the HIV/AIDS Epidemic
December 2007
■ People living with HIV/AIDS: 33.2 million (30.6–36.1million)
■ Adults: 30.8 million (28.2–33.6 million)
– Women: 15.4 million (13.9 - 16.6 million)
■ Children under 15 years: 2.5 million (2.2 - 2.6 million)
Overview of HIV/AIDS 5
Estimated PLHIV by End of 2007:
33.2 Million (regional distribution)
North America
1.3 million
Caribbean
230,000
Latin America
1.6 million
Western Europe
760,000
North Africa
& Middle East
380,000
Sub-
Saharan
Africa
22.5
million
Eastern Europe
& Central Asia
1.6 million
East Asia & Pacific
800,000
South
& South-East Asia
4.0 million
Australia
& New
Zealand
75,000
Overview of HIV/AIDS 6
Overview of HIV/AIDS 7
Overview of HIV/AIDS 8
The Proportion of Female in PLHIV
Overview of HIV/AIDS 9
Global Summary of the
Epidemic, December 2007
■ People newly infected with HIV: 2.5 million (1.8-
4.1 million)
■ Adults: 2.1 million (1.4 - 3.6 million)
■ Children under 15 years: 420,000 (350,000 – 540,000)
■ Every single day over 6,800 persons infected
with HIV and MTCT contributed over 1600 every
day
Overview of HIV/AIDS 10
Overview of HIV/AIDS 11
Trend of the AIDS Epidemic in Female,
(1990-2007)
Overview of HIV/AIDS 12
Global & Sub-Saharan Africa Trend of the AIDS
Epidemic(1990-2007)
Overview of HIV/AIDS 13
Global Summary of the
Epidemic, December 2007
■ AIDS deaths in 2007: 2.1 million (1.9 – 2.4 million)
■ Adults: 1.7 million (1.6 – 2.1 million)
■ Children under 15 years: 330,000 (310,000 – 380,000)
Overview of HIV/AIDS 14
Estimated Adult and Child Deaths from HIV/AIDS end of
2007: 2.1 Million (regional picture)
North
America
21,000
Caribbean
11,000
Latin
America
58,000
Western
Europe
12,000
North Africa
& Middle
East
25,000
Sub-Saharan
Africa
1.6 million
Eastern Europe
& Central Asia
55,000
East Asia
& Pacific
32,000
South
& South-
East Asia
270,000
Australia
& New Zealand
1,400
Overview of HIV/AIDS 15
Global Summary of ART, December 2007
■ PLHIV accessing ART in low and mid income
countries has increased dramatically
■ ART 2003: Around 0.4 million
■ ART 2005: Around 1.3 million
■ ART 2007:Around 3million
Overview of HIV/AIDS 16
Overview of HIV/AIDS 17
Overview of HIV/AIDS 18
Scale up of ART
1. 2003: Around 0.4 million
2. 2005: Around 1.3 million
3. 2007:Around 3million
Overview of HIV/AIDS 19
The Essential findings of Epidemic
Current epidemiologic assessment findings
■ The global prevalence of HIV is remaining at the same level
■ There are localized reductions in prevalence in specific
countries
■ A reduction in HIV-associated deaths
■ A reduction in the number of annual new HIV infections
globally e.g. in 2004 estimate was over 13,500 per day
however in 2007 it is over 6,800 per day which might
attribute to different reasons
Overview of HIV/AIDS 20
The Essential findings contd.
■ Women and young(15-24) are disproportionately affected
by HIV/AIDS and the figure keeps on increasing
■ Even though the HIV prevalence stabilized in Sub-
Saharan Africa, the actual number of people infected
continues to grow because of ongoing new infections and
misconception on the increasing access to ART.
■ In 2007: more 68% of all people HIV-positive, 1.7 million
people new infection, 76% of all AIDS deaths live in Sub-
Saharan Africa
■ The southern Africa sub region is the hardest hit of the
sub-Saharan Africa by the pandemic, e.g., 8 countries
>15%
Overview of HIV/AIDS 21
The Essential findings contd.
The global and regional trends suggests the pandemic has
formed two broad patterns:
1. Generalized/high level epidemics sustained in the
general populations of many sub-Saharan African
countries, especially in the southern part of the continent
and
2. Concentrated/low level epidemics occurs in the rest of
the world among populations most at risk, i.e., MSM,
Injecting drug users, sex workers and their sexual
partners.
Overview of HIV/AIDS 22
Overview of HIV/AIDS in Ethiopia
Overview of HIV/AIDS 23
Historical Overview of HIV/AIDS
in Ethiopia
■ The beginning of the HIV in Ethiopia was assumed
1982 (urban 1982 & rural 1984)
■ 1984: The first evidence of HIV infection in Ethiopia
■ 1986: The first two AIDS cases reported to the
Ministry of Health
■ 1989: HIV/AIDS surveillance started
■ At present there are 115 surveillance sites (Urban:
40, Rural: 75)
Overview of HIV/AIDS 24
The Facts: HIV in Ethiopia (2)
■ National HIV prevalence rate: 2.3 % in 2009
■ Female: 2.8%
■ Male: 1.8%
■ Urban HIV seroprevalence rate: 7.7%
■ Rural HIV seroprevalence rate: 0.9%
■ Addis Ababa seroprevalence rate: 8.5%
■ HIV infections occurring among adults between
15-49 years: more than 85%
Overview of HIV/AIDS 25
The Facts: HIV in Ethiopia (3)
■ 1.1million living with HIV/AIDS
■ 73,000 children (<15 years)
■ 131,145 New Infection (2009)
■ Annual HIV Incidence in 2009= 0.28%
■ 336,160 ART need in 2009
■ 44,751 AIDS deaths in 2009
■ HIV seems to be driving the TB epidemic (figure)
■ Life expectancy decreased due to AIDS= 3.9 years (2007)
Source: MOH/Policy Project: Aids in Ethiopia, 5th ed., July, 2004
Overview of HIV/AIDS 26
The Est. Distribution by Age of PLHIV
Age Distribution of PLHIV Estimate (AIDS 6th Report)
0% 6%
3%
1%
85%
5%
0%
Age 0-4 5-9 10-14 15-49 50-64 >65
Ref: AIDS 6th Report
Overview of HIV/AIDS 27
The Estimated Distribution of PLHIV by Sex &
Age (AIDS 6th Report)
Overview of HIV/AIDS 28
1. Socio-cultural Norms and Practices
■ Unprotected Sexual practice & concurrent multiple sexual practice
■ Low socio-economic status of women
2. Low condom use
3. Low level of comprehensive knowledge (EDHS 2005
F=16%, M=30% )
4. High rural-urban migration
5. Economic and Education
Therefore: We Need SOCIAL TRANSFORMATION:(BPR)
Why High Spread of HIV in Ethiopia?
Overview of HIV/AIDS 29
Impact of HIV/AIDS in Ethiopia
Overview of HIV/AIDS 30
Impacts of HIV/AIDS
HIV/AIDS has deep-rooted and whole negative
impact on
1. Economical( household, national, global)
2. Social
3. Political
4. Health Related
Overview of HIV/AIDS 31
Impacts
1. Economic (1)
A. Impact on Urban and Rural Households
■ Loss of income resulted from
■ Loss of labor as it affects the productive age groups
■ Loss of skilled manpower and knowledge
■ Loss of land
■ Loss of remittances
■ Reduction in savings and investment because of
■ Expenses for treatment, funeral, teskar
■ Need to sell livestock to meet expenses
■ Need to sell houses and resources
Overview of HIV/AIDS 32
Impact
1. Economic (2)
B. Impact on Industry
■ Loss of workers
■ Expenses for recruiting and training replacements
■ Reduced productivity in cases of skilled workers or managers
■ Lost work days due to sickness
■ 30 - 240 days per year
■ Lost work days due to funeral leave
■ Increased health care costs
■ 50% illness due to AIDS
■ Loss of skilled professionals
Overview of HIV/AIDS 33
Impact
2. Health
1. Suffering from broad OIs and suffer from diseases
2. Increase the prevalence of TB, e.g., in 2005 32%
of 141,000 TB cases accounted for HIV/AIDS and
in 2010 is 30% of 163,000 cases
3. High bed occupancy rate and chronic cases
increment
4. Decrease life expectancy at Birth
5. High health related costs
Overview of HIV/AIDS 34
National Response
Overview of HIV/AIDS 35
National Responses
1. Establishment of national and regional offices that
can respond to the pandemic
2. Development of policy, guideline and M&E tools
3. Capacity building (HR, Infrastructure, Systems)
4. Mobilization of Resources (GFATM, PEPFAR, UN
organization, World Bank, multilateral and
bilateral organizations)
5. Scale up of the prevention, care and treatment
services
Overview of HIV/AIDS 36
National Response (2)
■ National HIV/AIDS Task force established in 1985
■ National AIDS Control Program (NACP) established in MOH in 1986
■ HIV/AIDS Surveillance Activity started in 1989
■ HIV/AIDS Policy formulated by MOH and adopted by the Council of Ministers in
1998
■ Created an enabling atmosphere for HIV/AIDS prevention and control
■ Supplemented existing Health Policy, Women’s Policy, and Education and Training
Policy
■ Called for a multi-sectoral response
■ Guaranteed rights of PLHIV
■ HIV/AIDS Prevention & Control Office (HAPCO) established June 2002 and
regions also established a coordinating body after working as National
HIV/AIDS Council Secretariat NACS (since April 2000)
■ ARV Drugs Supply & Use Policy formulated July 2002
Overview of HIV/AIDS 37
National Response (3)
■ HAPCO Primarily responsible for
■ Resource Mobilization
■ Advocacy
■ Coordination of the sectoral responses
■ National Fund raising and grant proposal were successful &
able to win GFATM R2, R4, R7 and Rolling Continuation
Chanel (RCC)
■ The resources used for health system strengthening,
infrastructure, training and program management
Overview of HIV/AIDS 38
National Response (4)
■ HIV/AIDS Strategic plan for five years (2004 –
2006, 2007-2010) and new SPM onboard
■ Social mobilization & community involvement
■ Community ownership through the CC approach
■ Scaled up HIV/AIDS Programs
■ AIDS fund was initiated
■ Free ART program was scaled up
■ Free HCT services, PMTCT, OI and STI
Overview of HIV/AIDS 39
Policy on HIV/AIDS of the FDRE,
August 1998
 The Major objective is to provide an enabling
environment for the prevention and control of
HIV/AIDS in the country. And it emphasizes that
 HIV/AIDS is development problem and hence need multisectorial response
 The need to increase awareness and involvement of women (IEC/BCC)
 The need of multi source funds to mitigate the problem
 The need for holistic approach to provide care and treatment for PLHIV
 Cognizant the human right of PLHIV
 The catastrophic of the epidemic to the next generation that the
government wants to stands for
Overview of HIV/AIDS 40
Policy on HIV/AIDS
■ The HIV/AIDS Policy guide Prevention and Control
of HIV/AIDS
■ What are the prevention and Control activities?
Overview of HIV/AIDS 41
Policy on HIV/AIDS (Prevention Strategies)
1. Social mobilization (IEC/BCC)
2. HIV counseling and testing
■ Voluntary (VCT)
■ Provider initiated Testing and Counseling (PITC)
3. STI prevention and control
4. Condom promotion and Proper use
5. Infection prevention (IP) and Universal Precaution (UP)
6. Prevention of mother to child transmission (PMTCT)
7. Post exposure prophylaxis (PEP)
Overview of HIV/AIDS 42
Policy on HIV/AIDS
(Care, Rx and Support Strategies)
1. Care and Treatment
■ Palliative care
■ Community home based care
■ Opportunistic infection treatment
■ Tuberculosis treatment
■ Treatment of AIDS patients
2. Support for
■ Orphans and vulnerable children (OVC)
■ People living with HIV/AIDS (PLWHA)
Overview of HIV/AIDS 43
The Ten National HIV/AIDS
Intervention Strategies
Overview of HIV/AIDS 44
HIV/AIDS Intervention Strategies (1)
1. Targeted & Synchronized Social Mobilization
2. Established Implementation M-sms to support the Health
Network & continuum of Care Model
3. Expanded Comprehensive & Stdzed Prevention
Responses with in the health sector to avert new
infections
4. Accelerated enrollment in Comprehensive HIV/AIDS care
& Rx through established M-sms for intra-and inter-facility
linkages
5. Expanded HIV/AIDS services delivery capacity through
human resource development & adequate infrastructure
including equipment
Overview of HIV/AIDS 45
Eth HIV/AIDS Intervention Strategies (2)
6. Ensured Continuous supply of quality assured drugs &
medical supplies with appropriate pharmaceutical
services
7. Strengthen Lab capacity & ensured continuous supply of
all lab commodities
8. Strengthening M& E, IT, Operational Research & quality
assurance
9. Strengthened decentralized Roadmap management and
Coordination
10. Developed M-sms for Sustainability
Overview of HIV/AIDS 46
Ethiopian National ART Guidelines
Overview of HIV/AIDS 47
Table 2: First line Regimen for Adult and Adolescent
Recommended ARV Regimens for Adults and Adolescents:
One of the following should be used unless there are
contraindications:
Preferred :
 TDF+FTC(3TC) +EFV = triple FDC
 ZDV+3TC+EFV = combivir + EFV
 ZDV+3TC+NVP = triple FDC
Alternatives:
 D4T/3TC/EFV= double FDC(d4T/3TC)+ EFV
 TDF/3TC/NVP
 D4T/3TC/NVP= triple FDC
 ABC/3TC/EFV
 ABC/3TC/NVP
 ABC/3TC/ZDV= combivir + ABC
Overview of HIV/AIDS 48
Table 9: Second line Regimen for Adults and Adolescents
Overview of HIV/AIDS 49
The summary of different regimens
■ Refer to the table that summarizes the different
special scenarios and the regimens to be used in
those conditions (Participant Handbook)
Refer also the recent Guidelines
Overview of HIV/AIDS 50
HIV/AIDS Programs Major
Achievements; Challenges and
Initiatives to Address the
Challenges
Overview of HIV/AIDS 51
Major Achievements (1)
■ Formulated National HIV/AIDS Policy
■ Established National Coordinating body
■ Produced six editions of “AIDS in Ethiopia”
■ Formulated National ARV policy (revised and published in January
2005)
■ Developed SPM for HIV, e.g., Five-year strategic plan developed,
revised & updated
■ Drafted a Roadmap to accelerate access to HIV/AIDS care and
treatment
■ Developed M&E framework
■ Developed Robust Logistics Systems for HIV/AIDS commodities
(special of its kind)
Overview of HIV/AIDS 52
Major Achievements (2)
■ Key guidelines developed:
■ HIV Surveillance Guideline
■ HIV Surveillance Training Manual
■ Voluntary Counseling & Testing Guideline
■ AIDS Case Management Guideline
■ STI Management Guideline
■ Home-Based Care Guideline
■ Private HIV Labs Licensing Guideline
■ PMTCT Guideline
■ Home Care Training Manual
■ Counseling Training Manual
■ ARV Guideline
■ Universal Precautions & Post Exposure Prophylaxis
Overview of HIV/AIDS 53
Major Achievements (3)
■ Integrating HIV/AIDS into health programs:
■ Reproductive health
■ Mother and child health
■ Hospital hygiene
■ Health education
■ Integrated disease surveillance
■ TB/HIV Initiative
Overview of HIV/AIDS 54
Major Achievements (4)
■ Prevention, Diagnostics and Treatment centers as
of end of June 2009
1. 1525 HCT sites established
2. 115 (40 urban +75 rural) Sentinel Surveillance
sites established
3. 837 PMTCT sites established
4. 448 ART sites established
Overview of HIV/AIDS 55
HAART and Progress
 In July 2003, the government adopted the policy of ARV
drug supply and use; and subsidized cost ART was started
in some hospitals (Zewditu Hospital).
 In January, 2005 the government launched the free ARV
treatment initiative.
 Free based ART program was started in March, 2005.
 As of end of June 2009 more than 206,628 people Do
access ARV
Major Achievements (5)
Overview of HIV/AIDS 56
Trend on Service Expansion (HAPCO June
2009)
837
3
484
129
184
408
719
353
272
93
1525
1336
1005
775
658
0
200
400
600
800
1000
1200
1400
1600
1800
2004/05 2005/06 2006/07 2007/08 2008/09
#
of
Health
facilties
PMTCT ART VCT
Overview of HIV/AIDS 57
VCT trends (HAPCO June 2009)
436,854
564,351
1,922,666
4,559,954
5,800,248
-
1,000,000
2,000,000
3,000,000
4,000,000
5,000,000
6,000,000
Number
of
People
counseled
&
tested
per
year
2004/5 2005/6 2006/7 2007/8 2008/9
Year
Trend of Counseling and testing, 2004/5-2008/9
Overview of HIV/AIDS 58
Care and Treatment Trends
321548
387000
180477
206628
132239
153000
161529
39489
13773 24236
95,908
8276
3880
72,100
18594
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
2005 2006 2007 2008 2009
#of
people
Ever Enrolled Ever Started Currenlty on ART
Adult & Children Accessing ART & Chronic Care
Overview of HIV/AIDS 59
Challenges related to ART
 Shortage and high attrition of Human resources for health
 Increased number of LFU cases
 Non-adherence to care & Rx
 Inadequate Linkage between the various HIV services
 Stigma and discrimination
 Inadequate behavioural change
 Limited Financial Resources
 Lack of Comprehensives Data System
Overview of HIV/AIDS 60
Initiatives in addressing the challenges
 Task-shifting- to create better access to services
 Introduction of Simplified Rx approaches & DF(FDC)
 Clinical Mentoring to maintain quality
 Targeted and synchronized social mobilization
 Adherence and Retention support
 Realizing the Health net-work model
 Targeting at most at risk population groups
 Positive living (Prevention with Positives)
 Resource Mobilization and Coordination
Overview of HIV/AIDS 61
Key Points (1)
■ AIDS is a global, regional, and national crisis
■ Sub-Saharan Africa (>68%) is the most hit region
and female are highly affected (>60%)in this region
■ There are generalized/high level and
concentrated/low level epidemic and Ethiopia is in
state of generalized epidemic
■ The national HIV seroprevalence rate in Ethiopia is
2.3 % for 2009, and above 85% of HIV infections
occur among adults 15-49 years of age.
Overview of HIV/AIDS 62
Key Points (2)
■ HAART started in 1996 worldwide, however,
started in 2003 in Ethiopia.
■ Ethiopia has managed to test, and enroll more
people in short time and expected to go more to
reach UA
■ There are numerous guidelines, clear policy
direction, capacity building and service expansion
in Ethiopia.
■ There are 206,628 people on ART as of June 2009
and expected to increase to 397,818 (UA) by Dec
2010
Overview of HIV/AIDS 63
The Red Ribbon is the global symbol for solidarity
with HIV positive and people living with HIV/AIDS
and it unites the people in the common fight
against this disease.

More Related Content

What's hot

Health economics
Health economicsHealth economics
Health economics
Dr. Eman M. Mortada
 
Health care finance and budget
Health care finance and budgetHealth care finance and budget
Health care finance and budget
Vaishnavi Madhavan
 
Universal Health Coverage
Universal Health CoverageUniversal Health Coverage
Universal Health Coverage
Alakananda Banerjee
 
Introduction to Epidemiology
Introduction to EpidemiologyIntroduction to Epidemiology
Introduction to Epidemiology
Naveen Phuyal
 
Millennium Development Goals
Millennium Development Goals Millennium Development Goals
Millennium Development Goals
Confederation of Indian Industry
 
Primary health care system in nepal
Primary health care system in nepalPrimary health care system in nepal
Primary health care system in nepal
Rajan Chaudhary
 
NATIONAL VIRAL HEPATITIS CONTROL PROGRAM
NATIONAL VIRAL HEPATITIS CONTROL PROGRAMNATIONAL VIRAL HEPATITIS CONTROL PROGRAM
NATIONAL VIRAL HEPATITIS CONTROL PROGRAM
DrPANKAJCHAUDHARY1
 
The final ihr
The final ihrThe final ihr
The final ihr
kavita yadav
 
Neglected tropical diseases In India
Neglected tropical diseases In India Neglected tropical diseases In India
Neglected tropical diseases In India
S.Varuni .
 
Neglected Tropical Diseases
Neglected Tropical DiseasesNeglected Tropical Diseases
Neglected Tropical Diseases
Sindhu Ravichandran
 
Disease for control elimination & eradication
Disease for control elimination & eradication Disease for control elimination & eradication
Disease for control elimination & eradication
RINSAVAHEED1
 
Emerging &amp; re emerging infectious diseases
Emerging &amp; re emerging infectious diseasesEmerging &amp; re emerging infectious diseases
Emerging &amp; re emerging infectious diseases
mebinninan
 
International health
International healthInternational health
International health
Subraham Pany
 
National health programs and policies for prevention and control of ncds in n...
National health programs and policies for prevention and control of ncds in n...National health programs and policies for prevention and control of ncds in n...
National health programs and policies for prevention and control of ncds in n...
Pawan Dhami
 
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptxAPPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
Anjali Singh
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
SASMITANAYAK28
 
Integrated surveillance for communicable diseases
Integrated surveillance for communicable diseasesIntegrated surveillance for communicable diseases
Integrated surveillance for communicable diseases
WHO Regional Office for the Eastern Mediterranean
 
High impact interventions in rmnch+a(mch) for itc
High impact interventions in rmnch+a(mch) for itcHigh impact interventions in rmnch+a(mch) for itc
High impact interventions in rmnch+a(mch) for itc
Sudha Goel
 

What's hot (20)

Health economics
Health economicsHealth economics
Health economics
 
Health care finance and budget
Health care finance and budgetHealth care finance and budget
Health care finance and budget
 
Epidemiologic Transition
Epidemiologic Transition Epidemiologic Transition
Epidemiologic Transition
 
Universal Health Coverage
Universal Health CoverageUniversal Health Coverage
Universal Health Coverage
 
Introduction to Epidemiology
Introduction to EpidemiologyIntroduction to Epidemiology
Introduction to Epidemiology
 
Millennium Development Goals
Millennium Development Goals Millennium Development Goals
Millennium Development Goals
 
Primary health care system in nepal
Primary health care system in nepalPrimary health care system in nepal
Primary health care system in nepal
 
Global health
Global healthGlobal health
Global health
 
NATIONAL VIRAL HEPATITIS CONTROL PROGRAM
NATIONAL VIRAL HEPATITIS CONTROL PROGRAMNATIONAL VIRAL HEPATITIS CONTROL PROGRAM
NATIONAL VIRAL HEPATITIS CONTROL PROGRAM
 
The final ihr
The final ihrThe final ihr
The final ihr
 
Neglected tropical diseases In India
Neglected tropical diseases In India Neglected tropical diseases In India
Neglected tropical diseases In India
 
Neglected Tropical Diseases
Neglected Tropical DiseasesNeglected Tropical Diseases
Neglected Tropical Diseases
 
Disease for control elimination & eradication
Disease for control elimination & eradication Disease for control elimination & eradication
Disease for control elimination & eradication
 
Emerging &amp; re emerging infectious diseases
Emerging &amp; re emerging infectious diseasesEmerging &amp; re emerging infectious diseases
Emerging &amp; re emerging infectious diseases
 
International health
International healthInternational health
International health
 
National health programs and policies for prevention and control of ncds in n...
National health programs and policies for prevention and control of ncds in n...National health programs and policies for prevention and control of ncds in n...
National health programs and policies for prevention and control of ncds in n...
 
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptxAPPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
APPLICATION OF COMPUTERS IN EPIDEMIOLOGY AND PUBLIC HEALTH - ANJALI MAM.pptx
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
Integrated surveillance for communicable diseases
Integrated surveillance for communicable diseasesIntegrated surveillance for communicable diseases
Integrated surveillance for communicable diseases
 
High impact interventions in rmnch+a(mch) for itc
High impact interventions in rmnch+a(mch) for itcHigh impact interventions in rmnch+a(mch) for itc
High impact interventions in rmnch+a(mch) for itc
 

Similar to Overview of HIVAIDS in Ethiopia.ppt

Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
hetalmalaviya
 
Emerging and re-emerging infectious diseases: a key issue of governance for h...
Emerging and re-emerging infectious diseases: a key issue of governance for h...Emerging and re-emerging infectious diseases: a key issue of governance for h...
Emerging and re-emerging infectious diseases: a key issue of governance for h...
WHO Regional Office for Europe
 
Post 2015 agenda & aids coordination
Post 2015 agenda & aids coordinationPost 2015 agenda & aids coordination
Post 2015 agenda & aids coordinationAIDS Watch Africa
 
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
AMANUELMELAKU5
 
OVEARVIEW OF NON-COMMUNICABLE DISEASES IN LEOTHO
OVEARVIEW  OF NON-COMMUNICABLE DISEASES  IN LEOTHO   OVEARVIEW  OF NON-COMMUNICABLE DISEASES  IN LEOTHO
OVEARVIEW OF NON-COMMUNICABLE DISEASES IN LEOTHO
SEJOJO PHAAROE
 
Seminar on hiv
Seminar on hivSeminar on hiv
Seminar on hiv
sirjana Tiwari
 
seminaronhiv-180201064407.pdf
seminaronhiv-180201064407.pdfseminaronhiv-180201064407.pdf
seminaronhiv-180201064407.pdf
mZOn2
 
Towards a world without AIDS
Towards a world without AIDSTowards a world without AIDS
Towards a world without AIDS
Dr.Mahmoud Abbas
 
Raviglionemilano14 3-2013-130325105725-phpapp01
Raviglionemilano14 3-2013-130325105725-phpapp01Raviglionemilano14 3-2013-130325105725-phpapp01
Raviglionemilano14 3-2013-130325105725-phpapp01supermary2
 
Positively alive wad_presentation
Positively alive wad_presentationPositively alive wad_presentation
Positively alive wad_presentationAlan Brand
 
Unaids fact HIV
Unaids fact HIVUnaids fact HIV
Unaids fact HIV
Юлія Банкова
 
Neglecgted tropical disease: in context to Nepal
Neglecgted tropical disease: in context to NepalNeglecgted tropical disease: in context to Nepal
Neglecgted tropical disease: in context to Nepaldipesh125
 
HIV epidemic situation in Nepal
HIV epidemic situation in NepalHIV epidemic situation in Nepal
HIV epidemic situation in NepalBigyan Ojha
 
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction Strategies
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction StrategiesInjecting Drug Use, HIV/AIDS Epidemic and Harm Reduction Strategies
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction StrategiesSketchpowder, Inc.
 
07 Trend in ethiopia for last 26 years.pdf
07 Trend in ethiopia for last 26 years.pdf07 Trend in ethiopia for last 26 years.pdf
07 Trend in ethiopia for last 26 years.pdf
AMANUELMELAKU5
 
Dpseea model on tb
Dpseea model on tbDpseea model on tb
Dpseea model on tb
Basanta Chalise
 
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
StopTb Italia
 
Gender dimension of HIV/AIDS among young girls
Gender dimension of HIV/AIDS among young girlsGender dimension of HIV/AIDS among young girls
Gender dimension of HIV/AIDS among young girls
Sumaiya Akter Snigdha
 
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...Evaluate the geographic impact of HIV/AIDS at the local, national and interna...
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...Tom McLean
 

Similar to Overview of HIVAIDS in Ethiopia.ppt (20)

Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
Cmoathensrdkeynotespeechinfectdiseasesedited 140306043900-phpapp02
 
Emerging and re-emerging infectious diseases: a key issue of governance for h...
Emerging and re-emerging infectious diseases: a key issue of governance for h...Emerging and re-emerging infectious diseases: a key issue of governance for h...
Emerging and re-emerging infectious diseases: a key issue of governance for h...
 
Post 2015 agenda & aids coordination
Post 2015 agenda & aids coordinationPost 2015 agenda & aids coordination
Post 2015 agenda & aids coordination
 
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
01 Aynalem_Adugna_HIV_AIDS_in_Ethiopia.pdf
 
OVEARVIEW OF NON-COMMUNICABLE DISEASES IN LEOTHO
OVEARVIEW  OF NON-COMMUNICABLE DISEASES  IN LEOTHO   OVEARVIEW  OF NON-COMMUNICABLE DISEASES  IN LEOTHO
OVEARVIEW OF NON-COMMUNICABLE DISEASES IN LEOTHO
 
Seminar on hiv
Seminar on hivSeminar on hiv
Seminar on hiv
 
seminaronhiv-180201064407.pdf
seminaronhiv-180201064407.pdfseminaronhiv-180201064407.pdf
seminaronhiv-180201064407.pdf
 
Towards a world without AIDS
Towards a world without AIDSTowards a world without AIDS
Towards a world without AIDS
 
Raviglionemilano14 3-2013-130325105725-phpapp01
Raviglionemilano14 3-2013-130325105725-phpapp01Raviglionemilano14 3-2013-130325105725-phpapp01
Raviglionemilano14 3-2013-130325105725-phpapp01
 
Positively alive wad_presentation
Positively alive wad_presentationPositively alive wad_presentation
Positively alive wad_presentation
 
The Hiv Aid
The Hiv AidThe Hiv Aid
The Hiv Aid
 
Unaids fact HIV
Unaids fact HIVUnaids fact HIV
Unaids fact HIV
 
Neglecgted tropical disease: in context to Nepal
Neglecgted tropical disease: in context to NepalNeglecgted tropical disease: in context to Nepal
Neglecgted tropical disease: in context to Nepal
 
HIV epidemic situation in Nepal
HIV epidemic situation in NepalHIV epidemic situation in Nepal
HIV epidemic situation in Nepal
 
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction Strategies
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction StrategiesInjecting Drug Use, HIV/AIDS Epidemic and Harm Reduction Strategies
Injecting Drug Use, HIV/AIDS Epidemic and Harm Reduction Strategies
 
07 Trend in ethiopia for last 26 years.pdf
07 Trend in ethiopia for last 26 years.pdf07 Trend in ethiopia for last 26 years.pdf
07 Trend in ethiopia for last 26 years.pdf
 
Dpseea model on tb
Dpseea model on tbDpseea model on tb
Dpseea model on tb
 
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
PPT Gargioni "The Global Burden of Tuberculosis: Epidemiology and operational...
 
Gender dimension of HIV/AIDS among young girls
Gender dimension of HIV/AIDS among young girlsGender dimension of HIV/AIDS among young girls
Gender dimension of HIV/AIDS among young girls
 
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...Evaluate the geographic impact of HIV/AIDS at the local, national and interna...
Evaluate the geographic impact of HIV/AIDS at the local, national and interna...
 

More from Haramaya University

PHARMACEUTICAL ANALYSIS-II.ppt
PHARMACEUTICAL ANALYSIS-II.pptPHARMACEUTICAL ANALYSIS-II.ppt
PHARMACEUTICAL ANALYSIS-II.ppt
Haramaya University
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
Haramaya University
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
Haramaya University
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
Haramaya University
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
Haramaya University
 
DRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdfDRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdf
Haramaya University
 
DRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdfDRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdf
Haramaya University
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
Haramaya University
 
INTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptxINTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptx
Haramaya University
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
Haramaya University
 
INTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptxINTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptx
Haramaya University
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
Haramaya University
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
Haramaya University
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
Haramaya University
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
Haramaya University
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
Haramaya University
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
Haramaya University
 
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdfTirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
Haramaya University
 
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdfRenal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
Haramaya University
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
Haramaya University
 

More from Haramaya University (20)

PHARMACEUTICAL ANALYSIS-II.ppt
PHARMACEUTICAL ANALYSIS-II.pptPHARMACEUTICAL ANALYSIS-II.ppt
PHARMACEUTICAL ANALYSIS-II.ppt
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
 
PHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptx
 
DRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdfDRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdf
 
DRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdfDRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdf
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
INTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptxINTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptx
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
INTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptxINTEGRATED THERAPEUTICS I.pptx
INTEGRATED THERAPEUTICS I.pptx
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
 
UPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptxUPTODATE INFORMATION.pptx
UPTODATE INFORMATION.pptx
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
 
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdfTirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdf
 
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdfRenal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
Renal and Cardiovascular Outcomes with Efpeglenatide in Type 2 Diabetes.pdf
 
LITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptx
 

Recently uploaded

Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 

Recently uploaded (20)

Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 

Overview of HIVAIDS in Ethiopia.ppt

  • 1. Overview of HIV/AIDS In Ethiopia Unit 1 HIV Care and ART: A Course for Pharmacists by Salahadin M.Ali
  • 2. Overview of HIV/AIDS 2 Learning Objectives ■ Describe global & national HIV/AIDS epidemiological profile ■ Describe the Ethiopian National AIDS Policy ■ Describe the Ethiopian National Strategy for Prevention and Control of HIV/AIDS ■ Understand Implementation status of HIV/AIDS program in Ethiopia
  • 3. Global and National Summary of HIV/AIDS Epidemic
  • 4. Overview of HIV/AIDS 4 Global Summary of the HIV/AIDS Epidemic December 2007 ■ People living with HIV/AIDS: 33.2 million (30.6–36.1million) ■ Adults: 30.8 million (28.2–33.6 million) – Women: 15.4 million (13.9 - 16.6 million) ■ Children under 15 years: 2.5 million (2.2 - 2.6 million)
  • 5. Overview of HIV/AIDS 5 Estimated PLHIV by End of 2007: 33.2 Million (regional distribution) North America 1.3 million Caribbean 230,000 Latin America 1.6 million Western Europe 760,000 North Africa & Middle East 380,000 Sub- Saharan Africa 22.5 million Eastern Europe & Central Asia 1.6 million East Asia & Pacific 800,000 South & South-East Asia 4.0 million Australia & New Zealand 75,000
  • 8. Overview of HIV/AIDS 8 The Proportion of Female in PLHIV
  • 9. Overview of HIV/AIDS 9 Global Summary of the Epidemic, December 2007 ■ People newly infected with HIV: 2.5 million (1.8- 4.1 million) ■ Adults: 2.1 million (1.4 - 3.6 million) ■ Children under 15 years: 420,000 (350,000 – 540,000) ■ Every single day over 6,800 persons infected with HIV and MTCT contributed over 1600 every day
  • 11. Overview of HIV/AIDS 11 Trend of the AIDS Epidemic in Female, (1990-2007)
  • 12. Overview of HIV/AIDS 12 Global & Sub-Saharan Africa Trend of the AIDS Epidemic(1990-2007)
  • 13. Overview of HIV/AIDS 13 Global Summary of the Epidemic, December 2007 ■ AIDS deaths in 2007: 2.1 million (1.9 – 2.4 million) ■ Adults: 1.7 million (1.6 – 2.1 million) ■ Children under 15 years: 330,000 (310,000 – 380,000)
  • 14. Overview of HIV/AIDS 14 Estimated Adult and Child Deaths from HIV/AIDS end of 2007: 2.1 Million (regional picture) North America 21,000 Caribbean 11,000 Latin America 58,000 Western Europe 12,000 North Africa & Middle East 25,000 Sub-Saharan Africa 1.6 million Eastern Europe & Central Asia 55,000 East Asia & Pacific 32,000 South & South- East Asia 270,000 Australia & New Zealand 1,400
  • 15. Overview of HIV/AIDS 15 Global Summary of ART, December 2007 ■ PLHIV accessing ART in low and mid income countries has increased dramatically ■ ART 2003: Around 0.4 million ■ ART 2005: Around 1.3 million ■ ART 2007:Around 3million
  • 18. Overview of HIV/AIDS 18 Scale up of ART 1. 2003: Around 0.4 million 2. 2005: Around 1.3 million 3. 2007:Around 3million
  • 19. Overview of HIV/AIDS 19 The Essential findings of Epidemic Current epidemiologic assessment findings ■ The global prevalence of HIV is remaining at the same level ■ There are localized reductions in prevalence in specific countries ■ A reduction in HIV-associated deaths ■ A reduction in the number of annual new HIV infections globally e.g. in 2004 estimate was over 13,500 per day however in 2007 it is over 6,800 per day which might attribute to different reasons
  • 20. Overview of HIV/AIDS 20 The Essential findings contd. ■ Women and young(15-24) are disproportionately affected by HIV/AIDS and the figure keeps on increasing ■ Even though the HIV prevalence stabilized in Sub- Saharan Africa, the actual number of people infected continues to grow because of ongoing new infections and misconception on the increasing access to ART. ■ In 2007: more 68% of all people HIV-positive, 1.7 million people new infection, 76% of all AIDS deaths live in Sub- Saharan Africa ■ The southern Africa sub region is the hardest hit of the sub-Saharan Africa by the pandemic, e.g., 8 countries >15%
  • 21. Overview of HIV/AIDS 21 The Essential findings contd. The global and regional trends suggests the pandemic has formed two broad patterns: 1. Generalized/high level epidemics sustained in the general populations of many sub-Saharan African countries, especially in the southern part of the continent and 2. Concentrated/low level epidemics occurs in the rest of the world among populations most at risk, i.e., MSM, Injecting drug users, sex workers and their sexual partners.
  • 22. Overview of HIV/AIDS 22 Overview of HIV/AIDS in Ethiopia
  • 23. Overview of HIV/AIDS 23 Historical Overview of HIV/AIDS in Ethiopia ■ The beginning of the HIV in Ethiopia was assumed 1982 (urban 1982 & rural 1984) ■ 1984: The first evidence of HIV infection in Ethiopia ■ 1986: The first two AIDS cases reported to the Ministry of Health ■ 1989: HIV/AIDS surveillance started ■ At present there are 115 surveillance sites (Urban: 40, Rural: 75)
  • 24. Overview of HIV/AIDS 24 The Facts: HIV in Ethiopia (2) ■ National HIV prevalence rate: 2.3 % in 2009 ■ Female: 2.8% ■ Male: 1.8% ■ Urban HIV seroprevalence rate: 7.7% ■ Rural HIV seroprevalence rate: 0.9% ■ Addis Ababa seroprevalence rate: 8.5% ■ HIV infections occurring among adults between 15-49 years: more than 85%
  • 25. Overview of HIV/AIDS 25 The Facts: HIV in Ethiopia (3) ■ 1.1million living with HIV/AIDS ■ 73,000 children (<15 years) ■ 131,145 New Infection (2009) ■ Annual HIV Incidence in 2009= 0.28% ■ 336,160 ART need in 2009 ■ 44,751 AIDS deaths in 2009 ■ HIV seems to be driving the TB epidemic (figure) ■ Life expectancy decreased due to AIDS= 3.9 years (2007) Source: MOH/Policy Project: Aids in Ethiopia, 5th ed., July, 2004
  • 26. Overview of HIV/AIDS 26 The Est. Distribution by Age of PLHIV Age Distribution of PLHIV Estimate (AIDS 6th Report) 0% 6% 3% 1% 85% 5% 0% Age 0-4 5-9 10-14 15-49 50-64 >65 Ref: AIDS 6th Report
  • 27. Overview of HIV/AIDS 27 The Estimated Distribution of PLHIV by Sex & Age (AIDS 6th Report)
  • 28. Overview of HIV/AIDS 28 1. Socio-cultural Norms and Practices ■ Unprotected Sexual practice & concurrent multiple sexual practice ■ Low socio-economic status of women 2. Low condom use 3. Low level of comprehensive knowledge (EDHS 2005 F=16%, M=30% ) 4. High rural-urban migration 5. Economic and Education Therefore: We Need SOCIAL TRANSFORMATION:(BPR) Why High Spread of HIV in Ethiopia?
  • 29. Overview of HIV/AIDS 29 Impact of HIV/AIDS in Ethiopia
  • 30. Overview of HIV/AIDS 30 Impacts of HIV/AIDS HIV/AIDS has deep-rooted and whole negative impact on 1. Economical( household, national, global) 2. Social 3. Political 4. Health Related
  • 31. Overview of HIV/AIDS 31 Impacts 1. Economic (1) A. Impact on Urban and Rural Households ■ Loss of income resulted from ■ Loss of labor as it affects the productive age groups ■ Loss of skilled manpower and knowledge ■ Loss of land ■ Loss of remittances ■ Reduction in savings and investment because of ■ Expenses for treatment, funeral, teskar ■ Need to sell livestock to meet expenses ■ Need to sell houses and resources
  • 32. Overview of HIV/AIDS 32 Impact 1. Economic (2) B. Impact on Industry ■ Loss of workers ■ Expenses for recruiting and training replacements ■ Reduced productivity in cases of skilled workers or managers ■ Lost work days due to sickness ■ 30 - 240 days per year ■ Lost work days due to funeral leave ■ Increased health care costs ■ 50% illness due to AIDS ■ Loss of skilled professionals
  • 33. Overview of HIV/AIDS 33 Impact 2. Health 1. Suffering from broad OIs and suffer from diseases 2. Increase the prevalence of TB, e.g., in 2005 32% of 141,000 TB cases accounted for HIV/AIDS and in 2010 is 30% of 163,000 cases 3. High bed occupancy rate and chronic cases increment 4. Decrease life expectancy at Birth 5. High health related costs
  • 34. Overview of HIV/AIDS 34 National Response
  • 35. Overview of HIV/AIDS 35 National Responses 1. Establishment of national and regional offices that can respond to the pandemic 2. Development of policy, guideline and M&E tools 3. Capacity building (HR, Infrastructure, Systems) 4. Mobilization of Resources (GFATM, PEPFAR, UN organization, World Bank, multilateral and bilateral organizations) 5. Scale up of the prevention, care and treatment services
  • 36. Overview of HIV/AIDS 36 National Response (2) ■ National HIV/AIDS Task force established in 1985 ■ National AIDS Control Program (NACP) established in MOH in 1986 ■ HIV/AIDS Surveillance Activity started in 1989 ■ HIV/AIDS Policy formulated by MOH and adopted by the Council of Ministers in 1998 ■ Created an enabling atmosphere for HIV/AIDS prevention and control ■ Supplemented existing Health Policy, Women’s Policy, and Education and Training Policy ■ Called for a multi-sectoral response ■ Guaranteed rights of PLHIV ■ HIV/AIDS Prevention & Control Office (HAPCO) established June 2002 and regions also established a coordinating body after working as National HIV/AIDS Council Secretariat NACS (since April 2000) ■ ARV Drugs Supply & Use Policy formulated July 2002
  • 37. Overview of HIV/AIDS 37 National Response (3) ■ HAPCO Primarily responsible for ■ Resource Mobilization ■ Advocacy ■ Coordination of the sectoral responses ■ National Fund raising and grant proposal were successful & able to win GFATM R2, R4, R7 and Rolling Continuation Chanel (RCC) ■ The resources used for health system strengthening, infrastructure, training and program management
  • 38. Overview of HIV/AIDS 38 National Response (4) ■ HIV/AIDS Strategic plan for five years (2004 – 2006, 2007-2010) and new SPM onboard ■ Social mobilization & community involvement ■ Community ownership through the CC approach ■ Scaled up HIV/AIDS Programs ■ AIDS fund was initiated ■ Free ART program was scaled up ■ Free HCT services, PMTCT, OI and STI
  • 39. Overview of HIV/AIDS 39 Policy on HIV/AIDS of the FDRE, August 1998  The Major objective is to provide an enabling environment for the prevention and control of HIV/AIDS in the country. And it emphasizes that  HIV/AIDS is development problem and hence need multisectorial response  The need to increase awareness and involvement of women (IEC/BCC)  The need of multi source funds to mitigate the problem  The need for holistic approach to provide care and treatment for PLHIV  Cognizant the human right of PLHIV  The catastrophic of the epidemic to the next generation that the government wants to stands for
  • 40. Overview of HIV/AIDS 40 Policy on HIV/AIDS ■ The HIV/AIDS Policy guide Prevention and Control of HIV/AIDS ■ What are the prevention and Control activities?
  • 41. Overview of HIV/AIDS 41 Policy on HIV/AIDS (Prevention Strategies) 1. Social mobilization (IEC/BCC) 2. HIV counseling and testing ■ Voluntary (VCT) ■ Provider initiated Testing and Counseling (PITC) 3. STI prevention and control 4. Condom promotion and Proper use 5. Infection prevention (IP) and Universal Precaution (UP) 6. Prevention of mother to child transmission (PMTCT) 7. Post exposure prophylaxis (PEP)
  • 42. Overview of HIV/AIDS 42 Policy on HIV/AIDS (Care, Rx and Support Strategies) 1. Care and Treatment ■ Palliative care ■ Community home based care ■ Opportunistic infection treatment ■ Tuberculosis treatment ■ Treatment of AIDS patients 2. Support for ■ Orphans and vulnerable children (OVC) ■ People living with HIV/AIDS (PLWHA)
  • 43. Overview of HIV/AIDS 43 The Ten National HIV/AIDS Intervention Strategies
  • 44. Overview of HIV/AIDS 44 HIV/AIDS Intervention Strategies (1) 1. Targeted & Synchronized Social Mobilization 2. Established Implementation M-sms to support the Health Network & continuum of Care Model 3. Expanded Comprehensive & Stdzed Prevention Responses with in the health sector to avert new infections 4. Accelerated enrollment in Comprehensive HIV/AIDS care & Rx through established M-sms for intra-and inter-facility linkages 5. Expanded HIV/AIDS services delivery capacity through human resource development & adequate infrastructure including equipment
  • 45. Overview of HIV/AIDS 45 Eth HIV/AIDS Intervention Strategies (2) 6. Ensured Continuous supply of quality assured drugs & medical supplies with appropriate pharmaceutical services 7. Strengthen Lab capacity & ensured continuous supply of all lab commodities 8. Strengthening M& E, IT, Operational Research & quality assurance 9. Strengthened decentralized Roadmap management and Coordination 10. Developed M-sms for Sustainability
  • 46. Overview of HIV/AIDS 46 Ethiopian National ART Guidelines
  • 47. Overview of HIV/AIDS 47 Table 2: First line Regimen for Adult and Adolescent Recommended ARV Regimens for Adults and Adolescents: One of the following should be used unless there are contraindications: Preferred :  TDF+FTC(3TC) +EFV = triple FDC  ZDV+3TC+EFV = combivir + EFV  ZDV+3TC+NVP = triple FDC Alternatives:  D4T/3TC/EFV= double FDC(d4T/3TC)+ EFV  TDF/3TC/NVP  D4T/3TC/NVP= triple FDC  ABC/3TC/EFV  ABC/3TC/NVP  ABC/3TC/ZDV= combivir + ABC
  • 48. Overview of HIV/AIDS 48 Table 9: Second line Regimen for Adults and Adolescents
  • 49. Overview of HIV/AIDS 49 The summary of different regimens ■ Refer to the table that summarizes the different special scenarios and the regimens to be used in those conditions (Participant Handbook) Refer also the recent Guidelines
  • 50. Overview of HIV/AIDS 50 HIV/AIDS Programs Major Achievements; Challenges and Initiatives to Address the Challenges
  • 51. Overview of HIV/AIDS 51 Major Achievements (1) ■ Formulated National HIV/AIDS Policy ■ Established National Coordinating body ■ Produced six editions of “AIDS in Ethiopia” ■ Formulated National ARV policy (revised and published in January 2005) ■ Developed SPM for HIV, e.g., Five-year strategic plan developed, revised & updated ■ Drafted a Roadmap to accelerate access to HIV/AIDS care and treatment ■ Developed M&E framework ■ Developed Robust Logistics Systems for HIV/AIDS commodities (special of its kind)
  • 52. Overview of HIV/AIDS 52 Major Achievements (2) ■ Key guidelines developed: ■ HIV Surveillance Guideline ■ HIV Surveillance Training Manual ■ Voluntary Counseling & Testing Guideline ■ AIDS Case Management Guideline ■ STI Management Guideline ■ Home-Based Care Guideline ■ Private HIV Labs Licensing Guideline ■ PMTCT Guideline ■ Home Care Training Manual ■ Counseling Training Manual ■ ARV Guideline ■ Universal Precautions & Post Exposure Prophylaxis
  • 53. Overview of HIV/AIDS 53 Major Achievements (3) ■ Integrating HIV/AIDS into health programs: ■ Reproductive health ■ Mother and child health ■ Hospital hygiene ■ Health education ■ Integrated disease surveillance ■ TB/HIV Initiative
  • 54. Overview of HIV/AIDS 54 Major Achievements (4) ■ Prevention, Diagnostics and Treatment centers as of end of June 2009 1. 1525 HCT sites established 2. 115 (40 urban +75 rural) Sentinel Surveillance sites established 3. 837 PMTCT sites established 4. 448 ART sites established
  • 55. Overview of HIV/AIDS 55 HAART and Progress  In July 2003, the government adopted the policy of ARV drug supply and use; and subsidized cost ART was started in some hospitals (Zewditu Hospital).  In January, 2005 the government launched the free ARV treatment initiative.  Free based ART program was started in March, 2005.  As of end of June 2009 more than 206,628 people Do access ARV Major Achievements (5)
  • 56. Overview of HIV/AIDS 56 Trend on Service Expansion (HAPCO June 2009) 837 3 484 129 184 408 719 353 272 93 1525 1336 1005 775 658 0 200 400 600 800 1000 1200 1400 1600 1800 2004/05 2005/06 2006/07 2007/08 2008/09 # of Health facilties PMTCT ART VCT
  • 57. Overview of HIV/AIDS 57 VCT trends (HAPCO June 2009) 436,854 564,351 1,922,666 4,559,954 5,800,248 - 1,000,000 2,000,000 3,000,000 4,000,000 5,000,000 6,000,000 Number of People counseled & tested per year 2004/5 2005/6 2006/7 2007/8 2008/9 Year Trend of Counseling and testing, 2004/5-2008/9
  • 58. Overview of HIV/AIDS 58 Care and Treatment Trends 321548 387000 180477 206628 132239 153000 161529 39489 13773 24236 95,908 8276 3880 72,100 18594 0 50000 100000 150000 200000 250000 300000 350000 400000 450000 2005 2006 2007 2008 2009 #of people Ever Enrolled Ever Started Currenlty on ART Adult & Children Accessing ART & Chronic Care
  • 59. Overview of HIV/AIDS 59 Challenges related to ART  Shortage and high attrition of Human resources for health  Increased number of LFU cases  Non-adherence to care & Rx  Inadequate Linkage between the various HIV services  Stigma and discrimination  Inadequate behavioural change  Limited Financial Resources  Lack of Comprehensives Data System
  • 60. Overview of HIV/AIDS 60 Initiatives in addressing the challenges  Task-shifting- to create better access to services  Introduction of Simplified Rx approaches & DF(FDC)  Clinical Mentoring to maintain quality  Targeted and synchronized social mobilization  Adherence and Retention support  Realizing the Health net-work model  Targeting at most at risk population groups  Positive living (Prevention with Positives)  Resource Mobilization and Coordination
  • 61. Overview of HIV/AIDS 61 Key Points (1) ■ AIDS is a global, regional, and national crisis ■ Sub-Saharan Africa (>68%) is the most hit region and female are highly affected (>60%)in this region ■ There are generalized/high level and concentrated/low level epidemic and Ethiopia is in state of generalized epidemic ■ The national HIV seroprevalence rate in Ethiopia is 2.3 % for 2009, and above 85% of HIV infections occur among adults 15-49 years of age.
  • 62. Overview of HIV/AIDS 62 Key Points (2) ■ HAART started in 1996 worldwide, however, started in 2003 in Ethiopia. ■ Ethiopia has managed to test, and enroll more people in short time and expected to go more to reach UA ■ There are numerous guidelines, clear policy direction, capacity building and service expansion in Ethiopia. ■ There are 206,628 people on ART as of June 2009 and expected to increase to 397,818 (UA) by Dec 2010
  • 63. Overview of HIV/AIDS 63 The Red Ribbon is the global symbol for solidarity with HIV positive and people living with HIV/AIDS and it unites the people in the common fight against this disease.